» Articles » PMID: 37351512

PARP-1: a Critical Regulator in Radioprotection and Radiotherapy-mechanisms, Challenges, and Therapeutic Opportunities

Overview
Journal Front Pharmacol
Date 2023 Jun 23
PMID 37351512
Authors
Affiliations
Soon will be listed here.
Abstract

Since its discovery, poly (ADP-ribose) polymerase 1 (PARP-1) has been extensively studied due to its regulatory role in numerous biologically crucial pathways. PARP inhibitors have opened new therapeutic avenues for cancer patients and have gained approval as standalone treatments for certain types of cancer. With continued advancements in the research of PARP inhibitors, we can fully realize their potential as therapeutic targets for various diseases. To assess the current understanding of PARP-1 mechanisms in radioprotection and radiotherapy based on the literature. We searched the PubMed database and summarized information on PARP inhibitors, the interaction of PARP-1 with DNA, and the relationships between PARP-1 and p53/ROS, NF-κB/DNA-PK, and caspase3/AIF, respectively. The enzyme PARP-1 plays a crucial role in repairing DNA damage and modifying proteins. Cells exposed to radiation can experience DNA damage, such as single-, intra-, or inter-strand damage. This damage, associated with replication fork stagnation, triggers DNA repair mechanisms, including those involving PARP-1. The activity of PARP-1 increases 500-fold on DNA binding. Studies on PARP-1-knockdown mice have shown that the protein regulates the response to radiation. A lack of PARP-1 also increases the organism's sensitivity to radiation injury. PARP-1 has been found positively or negatively regulate the expression of specific genes through its modulation of key transcription factors and other molecules, including NF-κB, p53, Caspase 3, reactive oxygen species (ROS), and apoptosis-inducing factor (AIF). This review provides a comprehensive analysis of the physiological and pathological roles of PARP-1 and examines the impact of PARP-1 inhibitors under conditions of ionizing radiation exposure. The review also emphasizes the challenges and opportunities for developing PARP-1 inhibitors to improve the clinical outcomes of ionizing radiation damage.

Citing Articles

RELT Is Upregulated in Breast Cancer and Induces Death in Breast Cancer Cells.

Batiste M, Joy B, Yee C, Cho L, Christensen A, Abed I Biomedicines. 2025; 12(12.

PMID: 39767574 PMC: 11727564. DOI: 10.3390/biomedicines12122667.


Effective Radiosensitization of HNSCC Cell Lines by DNA-PKcs Inhibitor AZD7648 and PARP Inhibitors Talazoparib and Niraparib.

Mentzel J, Hildebrand L, Kuhlmann L, Fietkau R, Distel L Int J Mol Sci. 2024; 25(11).

PMID: 38891817 PMC: 11172136. DOI: 10.3390/ijms25115629.


A multi-site phase I trial of Veliparib with standard radiation and temozolomide in patients with newly diagnosed glioblastoma multiforme (GBM).

Kleinberg L, Ye X, Supko J, Stevens G, Shu H, Mikkelsen T J Neurooncol. 2023; 165(3):499-507.

PMID: 38015376 DOI: 10.1007/s11060-023-04514-0.

References
1.
Curtin N . DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer. 2012; 12(12):801-17. DOI: 10.1038/nrc3399. View

2.
Pilie P, Gay C, Byers L, OConnor M, Yap T . PARP Inhibitors: Extending Benefit Beyond -Mutant Cancers. Clin Cancer Res. 2019; 25(13):3759-3771. DOI: 10.1158/1078-0432.CCR-18-0968. View

3.
DAmours D, Desnoyers S, DSilva I, Poirier G . Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J. 1999; 342 ( Pt 2):249-68. PMC: 1220459. View

4.
Chalmers A, Johnston P, Woodcock M, Joiner M, Marples B . PARP-1, PARP-2, and the cellular response to low doses of ionizing radiation. Int J Radiat Oncol Biol Phys. 2004; 58(2):410-9. DOI: 10.1016/j.ijrobp.2003.09.053. View

5.
Spagnolo L, Barbeau J, Curtin N, Morris E, Pearl L . Visualization of a DNA-PK/PARP1 complex. Nucleic Acids Res. 2012; 40(9):4168-77. PMC: 3351162. DOI: 10.1093/nar/gkr1231. View